Category: Pharmacology & Therapeutics
Keywords: sugammadex, rocuronium, NMBA, vecuronium (PubMed Search)
After three failed attempts, the FDA finally granted approval for Merck's non-depolarizing neuromuscular blocker reversal agent sugammadex (Bridion). Though the product has been used in Europe and Asia for several years, hypersensitivity concerns led to the delayed approval in the U.S.
Application to Clinical Practice
The EM PharmD blog discusses sugammadex's approval in more detail.
Follow me on Twitter (@PharmERToxGuy)